Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Eckert & Ziegler Strahlen- und Medizintechnik AG €13.73, price €12.36, upside +11.1%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Eckert & Ziegler Strahlen- und Medizintechnik AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €8.12 – €37.22 · fair‑value band €9.62 – €17.85 · the €12.36 price screens below the €13.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Eckert & Ziegler Strahlen- und Medizintechnik in your weekly email
Every Wednesday you see whether Eckert & Ziegler Strahlen- und Medizintechnik is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products.
Show more
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services. It offers standard and radiation sources for medical and industrial sectors; medical imaging and spect diagnostics, industrial analytical and instrument, high activity CS-137 and CO-60, and oil well logging sources; blood irradiators and environmental disposal source services; and bulk isotopes as well as calibration-related sources for radioisotopes. In addition, the company offers Tc-99m generators and supplies, trade in raw isotopes and other products, and services. It serves medical, scientific, and industrial applications. The company was formerly known as Eckert & Ziegler Strahlen- und Medizintechnik AG and changed its name to Eckert & Ziegler SE in March 2024. Eckert & Ziegler SE was founded in 1992 and is headquartered in Berlin, Germany.
Stock analysis
Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) currently trades at €12.36, while our model-based Fair Value estimate is €13.73, implying the stock looks roughly 10.0% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €16.90 per share, and 15 of the 26 models we run sit above the €12.36 price.
Bear case: the Dividend Discount group reads lowest at €2.13, and 11 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: €9.62 (bear) to €17.85 (bull), the price of €12.36 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Eckert & Ziegler Strahlen- und Medizintechnik AG reported revenue of €312M in FY2025 versus €180M in FY2021, a compound +14.7%/yr. Reported net income was €48.8M in FY2025, compounding +9.0%/yr from FY2021.
Key figures
Market cap €954M · P/E ratio 15.6 · P/S ratio 2.45 · EPS (TTM) €0.7900 · Dividend yield 1.8% · Net margin 15.6% · Return on equity 19.8% · Return on assets (EBIT) 12.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 11%, EUZ screens cheaper than that median.
Fair Value models
Bear €9.62Fair Value €13.73Bull €17.85
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.4170 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.96/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.1%
Start year 2020 (pandemic). Over 10 years: +8.3% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+13.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.5%
Dividend (yield on the price)1.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.17% vs 18%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 24%
2025 sits 66% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +12.5% a year for the price and +3.3% for the forecasts.
Compare Eckert & Ziegler Strahlen- und Medizintechnik AG with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks
Beats the industry median on 11/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside+11% · Top 25%
Profitability
Return on equity (TTM)20% · Top 25%
Return on assets10% · Top 25%
Net margin (TTM)16% · Top 25%
Operating margin (TTM)22% · Top 25%
Growth and dividend
Revenue growth7% · Above median
Dividend yield (TTM)1.8% · Below median
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Eckert & Ziegler Strahlen- und Medizintechnik AG Fair Value". https://www.fairvalue-calculator.com/stock/EUZ
Frequently asked questions
Is Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €13.73 versus a price of €12.36, about +11% upside (undervalued).
What is the fair value of EUZ?
Our model-based fair value for Eckert & Ziegler Strahlen- und Medizintechnik AG is €13.73 (as of Sep 23, 2026), built from audited fundamentals. The current price: €12.36.
What is the quality score of EUZ?
Eckert & Ziegler Strahlen- und Medizintechnik AG has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
Our model-based price target is the fair value of €13.73 (as of Sep 23, 2026) from 26 valuation models. Cautious scenario €9.62, optimistic scenario €17.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Eckert & Ziegler Strahlen- und Medizintechnik AG stock forecast for 2026?
Our models put fair value at €13.73, about +11% upside versus a price of €12.36 (undervalued). Cautious scenario €9.62, optimistic scenario €17.85. The calculation is refreshed regularly with new filings.
What is the revenue of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
Eckert & Ziegler Strahlen- und Medizintechnik AG reported trailing-twelve-month revenue of about €317M (latest available figure, as of Sep 23, 2026).
Does Eckert & Ziegler Strahlen- und Medizintechnik AG pay a dividend?
Eckert & Ziegler Strahlen- und Medizintechnik AG currently shows a dividend yield of about 1.78% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
For today's price to be fair in a discounted-cash-flow model, Eckert & Ziegler Strahlen- und Medizintechnik AG would have to grow free cash flow by +15.0 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.1 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of EUZ use?
Our models discount Eckert & Ziegler Strahlen- und Medizintechnik AG at 12.4 %: a base by market capitalisation (small), damped by beta 1.49, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Eckert & Ziegler Strahlen- und Medizintechnik AG that is +15.0 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) delivered so far?
Over the past 5 years revenue at Eckert & Ziegler Strahlen- und Medizintechnik AG grew +12.1 % a year. The price currently implies +15.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Eckert & Ziegler Strahlen- und Medizintechnik AG (+15.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
The free-cash-flow yield on the price is 4.43 %: that much free cash flow Eckert & Ziegler Strahlen- und Medizintechnik AG produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Eckert & Ziegler Strahlen- und Medizintechnik AG it is €13.73 per share (as of Sep 23, 2026), against a price of €12.36. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Eckert & Ziegler Strahlen- und Medizintechnik AG stock overvalued or undervalued in 2026?
As of Sep 23, 2026, EUZ trades below its calculated fair value: price €12.36, fair value €13.73, a gap of about +11% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EUZ?
No. The price is what the market pays today (€12.36); the fair value is what the company's own numbers justify (€13.73). For Eckert & Ziegler Strahlen- und Medizintechnik AG the two are €1.37 per share apart. That gap is exactly why we show both numbers side by side.
How much is Eckert & Ziegler Strahlen- und Medizintechnik AG worth?
The market values Eckert & Ziegler Strahlen- und Medizintechnik AG at about €954M (market capitalisation, as of Sep 23, 2026). Per share that is €12.36; our models calculate a fair value of €13.73 per share.
What do the bullish and bearish scenarios say about EUZ?
Our models span a range for Eckert & Ziegler Strahlen- und Medizintechnik AG: cautious scenario €9.62, base €13.73, optimistic €17.85 per share (as of Sep 23, 2026, price €12.36). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EUZ?
Eckert & Ziegler Strahlen- und Medizintechnik AG trades at a price-to-earnings ratio of 15.6 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €13.73 is built from several models across several years. Other multiples: PEG 0.9, P/B 4.3, P/S 3.4, EV/EBITDA 10.7.
What is the PEG ratio of EUZ?
The PEG ratio of Eckert & Ziegler Strahlen- und Medizintechnik AG is 0.91 (P/E divided by earnings growth, as of Sep 23, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
Balance-sheet figures for Eckert & Ziegler Strahlen- und Medizintechnik AG (as of Sep 23, 2026): return on equity 19.8%, debt of 0.03 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is EUZ from its 52-week high?
Eckert & Ziegler Strahlen- und Medizintechnik AG trades at €12.36, about 31% below its 52-week high of €17.83 and 3% above the low of €12.03 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of €13.73 is for.
Which stocks are comparable to Eckert & Ziegler Strahlen- und Medizintechnik AG?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Eckert & Ziegler Strahlen- und Medizintechnik AG stock attractive at the current price?
The data as of Sep 23, 2026: price €12.36, calculated fair value €13.73 (+11%), Quality Score 69/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EUZ calculated?
We run Eckert & Ziegler Strahlen- und Medizintechnik AG through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €13.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Eckert & Ziegler Strahlen- und Medizintechnik AG currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
The closing price on Sep 23, 2026 was €12.36. Our model-based fair value is €13.73, about +11% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Eckert & Ziegler Strahlen- und Medizintechnik AG right now?
A fairly wide model range (€9.62 to €17.85) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) come from?
Earnings per share at Eckert & Ziegler Strahlen- und Medizintechnik AG grew +16.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.8 %, EBIT margin +7.5 %, tax rate +0.6 %, residual (interest, one-offs) −0.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Eckert & Ziegler Strahlen- und Medizintechnik AG
How large is the market capitalisation of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
The market capitalisation of Eckert & Ziegler Strahlen- und Medizintechnik AG is €954M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
The price-to-sales ratio of Eckert & Ziegler Strahlen- und Medizintechnik AG is 2.45 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
Earnings per share at Eckert & Ziegler Strahlen- und Medizintechnik AG are €0.7900 (price ÷ EPS = P/E 15.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
The dividend yield of Eckert & Ziegler Strahlen- und Medizintechnik AG is 1.8% (payout 27.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
The net margin of Eckert & Ziegler Strahlen- und Medizintechnik AG is 15.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
The return on equity (ROE) of Eckert & Ziegler Strahlen- und Medizintechnik AG is 19.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
On an EBIT basis the return on assets of Eckert & Ziegler Strahlen- und Medizintechnik AG is 12.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
The operating margin of Eckert & Ziegler Strahlen- und Medizintechnik AG is 21.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
Revenue at Eckert & Ziegler Strahlen- und Medizintechnik AG is growing +7.0% versus a year earlier (3y avg +12.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)?
Earnings per share at Eckert & Ziegler Strahlen- und Medizintechnik AG are growing +6.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) hold?
Eckert & Ziegler Strahlen- und Medizintechnik AG holds more cash than debt, €83.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Eckert & Ziegler Strahlen- und Medizintechnik AG in the live analysis
One click puts Eckert & Ziegler Strahlen- und Medizintechnik AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
